Brief: Grail Announces First Participant Enrolled In Reach Study Evaluating Clinical Impact Of Galleri® Multi-Cancer Early Detection (Mced) Test In The Medicare Population
18/07/2024 14:22
July 18 (Reuters) - Grail Inc GRAL.O :
* GRAIL ANNOUNCES FIRST PARTICIPANT ENROLLED IN REACH STUDY
EVALUATING CLINICAL IMPACT OF GALLERI® MULTI-CANCER EARLY
DETECTION (MCED) TEST IN THE MEDICARE POPULATION
* GRAIL INC - MEDICARE TO COVER COSTS FOR GALLERI STUDY
PARTICIPANTS
Source text for Eikon: ID:nPn4l4Sffa
Further company coverage: GRAL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grail
See all newsGrail rises as TD Cowen more than doubles PT on FDA, Medicare optimism
Grail's cancer blood test nears landmark FDA approval, but insurance coverage looms
U.S. RESEARCH ROUNDUP-Chevron, Mobility Global, Tesla
Street View: Grail cancer test's progress boosts prospects for multi-cancer detection market
NASDAQ RESUMED AT 07:05 AM